Video
Molecular Testing in Early NSCLC to Guide Treatment Decision Making
Author(s):
Jonathan Spicer, MD, explains the role of molecular testing in patients with stage I-IIIA NSCLC, and how it informs treatment decision-making.
EP: 1.Recommendations for Molecular Testing in Non-Small Cell Lung Cancer (NSCLC)
Now Viewing
EP: 2.Molecular Testing in Early NSCLC to Guide Treatment Decision Making
EP: 3.Is There a Role for Liquid Biopsies in Early NSCLC?
EP: 4.Updates in the Treatment of Stage I-IIIA NSCLC
EP: 5.The Role of Neoadjuvant Therapy in Patients with Resectable NSCLC
EP: 6.Selecting Appropriate Patients with NSCLC for Neoadjuvant Therapy
EP: 7.The Role of Adjuvant Therapy in Patients with NSCLC
EP: 8.Updates on Adjuvant Osimertinib for NSCLC Treatment from the ADUARA Trial
EP: 9.Adjuvant Therapy in EGFR-Mutated NSCLC
EP: 10.NSCLC Molecular Testing Recommendations for Community Hospitals
EP: 11.Exciting NSCLC Data Updates from ESMO 2022
Related Videos
Related Content
